Clinical Trial: NCT05464433
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2025-03-13 |
Study Overview
Brief Summary
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy in combination with tislelizumab and mitoxantrone hydrochloride liposome combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）
Official Title
Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）
Conditions
Extranodal Natural Killer T Cell Lymphoma
Intervention / Treatment
- Drug: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
- Drug: Maintenance of tislelizumab
Other Study ID Numbers
- B2022-300
Start Date (Actual)
2022-06-23
Primary Completion Date (Estimated)
2025-04-30
Study Completion Date (Estimated)
2025-11-30
Enrollment (Estimated)
46
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Sun Yat-sen University |
| Information Provided By: | Sun Yat-sen University |
| Last Update Posted: | 2025-03-13 |
Study Overview
Brief Summary
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy in combination with tislelizumab and mitoxantrone hydrochloride liposome combination treatment in patients with relapsed or refractory Extranodal Natural Killer/T Cell Lymphoma（NKTCL）
Official Title
Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022）
Conditions
Extranodal Natural Killer T Cell Lymphoma
Intervention / Treatment
- Drug: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
- Drug: Maintenance of tislelizumab
Other Study ID Numbers
- B2022-300
Start Date (Actual)
2022-06-23
Primary Completion Date (Estimated)
2025-04-30
Study Completion Date (Estimated)
2025-11-30
Enrollment (Estimated)
46
Study Type
Interventional
Phase
Phase 1, Phase 2